According to Benli Technology's announcement, the company recently received the “Administrative Licensing Decision” issued by the Zhejiang Drug Administration and agreed to the company's “Pharmaceutical Production License” license change application. After the change, the company was located at the production address at No. 15, Donghai Sixth Avenue, Linhai, Zhejiang Province. The production scope was adjusted from “APIs” to “APIs”. The corresponding production line was a norfloxacin production line, involving A2, A4, and A5 workshops, and obtained a GMP compliance inspection for Zhejiang 2026 No. C0027. The scope of inspection was APIs. This change has no significant impact on the company's performance in the short term, and there is uncertainty about future product sales.

According to Benli Technology's announcement, the company recently received the “Administrative Licensing Decision” issued by the Zhejiang Drug Administration and agreed to the company's “Pharmaceutical Production License” license change application. After the change, the company was located at the production address at No. 15, Donghai Sixth Avenue, Linhai, Zhejiang Province. The production scope was adjusted from “APIs” to “APIs”. The corresponding production line was a norfloxacin production line, involving A2, A4, and A5 workshops, and obtained a GMP compliance inspection for Zhejiang 2026 No. C0027. The scope of inspection was APIs. This change has no significant impact on the company's performance in the short term, and there is uncertainty about future product sales.